Valuation: Unicycive Therapeutics, Inc.

Market Cap 206M 180M 166M 155M 292M 19.44B 299M 2B 772M 9.59B 772M 755M 33.29B P/E 2026 *
-7.88x
P/E 2027 * 1.2x
Enterprise Value 206M 180M 166M 155M 292M 19.44B 299M 2B 772M 9.59B 772M 755M 33.29B EV / Sales 2026 *
11.5x
EV / Sales 2027 * 0.59x
Free-Float
97.64%
Yield 2026 *
54.2%
Yield 2027 * 30.3%
1 day+7.99%
1 week-2.16%
Current month+4.34%
1 month+4.34%
3 months+20.50%
6 months+29.85%
Current year+33.45%
1 week 6.75
Extreme 6.75
8.56
1 month 6.65
Extreme 6.65
8.56
Current year 5.36
Extreme 5.36
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
87.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 2016-08-17
Director of Finance/CFO 64 2021-02-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 53 2016-08-17
Director/Board Member 58 2017-12-31
Director/Board Member 58 2023-09-05
Date Insider Type Main position Quantity % Market Cap.
May. 13Free

Executive/Senior Manager

169,500 0.6716%
May. 13Free

Chief Executive Officer

762,200 3.0201%
May. 13Free

Director

126,300 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
+7.99%-2.16%+13.24%-53.33% 206M
+2.22%-1.25%+70.88%+125.89% 55.78B
+6.76%+18.10%+91.66%+104.09% 55.66B
+3.33%+4.51%-11.68%-11.91% 23.84B
+1.32%+6.22%+5.28%+415.45% 22.7B
+6.11%+6.53%+38.40%-29.46% 16.12B
-0.89%+5.71%+24.30%+186.29% 13.64B
+9.96%+15.98%+157.65%+310.89% 14.8B
+2.85%+2.81%+75.32%+139.44% 12.16B
+6.17%+10.22%+163.15%+166.44% 11.85B
Average +4.60%+6.45%+62.82%+135.38% 22.68B
Weighted average by Cap. +4.22%+7.69%+66.29%+142.39%

Financials

2026 *2027 *
Net sales 17.83M 15.61M 14.41M 13.46M 25.34M 1.69B 25.91M 173M 66.96M 832M 66.96M 65.49M 2.89B 346M 303M 280M 261M 492M 32.74B 503M 3.37B 1.3B 16.15B 1.3B 1.27B 56.07B
Net income -39.64M -34.71M -32.04M -29.92M -56.32M -3.75B -57.6M -386M -149M -1.85B -149M -146M -6.42B 225M 197M 182M 170M 320M 21.28B 327M 2.19B 845M 10.5B 845M 827M 36.44B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
26-06-29 $7.700 +7.99% 2,593,482
26-06-26 $7.130 -13.15% 7,420,398
26-06-25 $8.210 +4.06% 1,275,115
26-06-24 $7.890 -1.62% 1,122,644
26-06-23 $8.020 +1.91% 1,753,147
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.700USD
Average target price
41.30USD
Spread / Average Target
+436.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock